Felix Korell, Lukas Entenmann, Sebastian Romann, Evangelos Giannitsis, Anita Schmitt, Carsten Müller-Tidow, Norbert Frey, Peter Dreger, Michael Schmitt, Lorenz H Lehmann
BACKGROUND: Assessment of cardiovascular risk is critical for patients with cancer. Previous retrospective studies suggest potential cardiotoxicity of CAR T cell therapies. We aimed to prospectively assess cardiotoxicity and the predictive value of cardiac biomarkers and classical risk factors (age, cardiac function, diabetes, arterial hypertension, smoking) for cardiac events and all-cause mortality (ACM). METHODS: In this prospective cohort study, all patients treated with CAR T cell constructs (axi-cel, tisa-cel, brexu-cel, ide-cel, or the 3rd generation CAR HD-CAR-1) from Oct 1, 2018, to Sept 30, 2022 at the University Hospital Heidelberg were included...
March 2024: EClinicalMedicine